Double Diabetes: When Type 1 Diabetes Meets Insulin Resistance

Published on
November 15, 2026

Symbiosis School of Biological Sciences, Pune, MH, India

Areas of Expertise
Functional genomics, Diabetes, Insulin resistance

A child with type 1 diabetes (T1D) whose insulin dose keeps rising while glucose control does not improve may have a second problem: insulin resistance. This combination is called double diabetes, and it matters because it is associated with a higher risk of diabetic complications. Two gaps hold back progress: we cannot reliably measure insulin resistance in T1D, and we have little evidence on how to treat it in young people.

Diabetes mellitus is characterised by persistently high blood glucose. Long-standing diabetes raises the risk of kidney, nerve, eye, and cardiovascular complications, with cardiovascular disease the leading cause of death. Diabetes is common and rising in India. T1D, the insulin-dependent form, is characterised by insufficient insulin production by the pancreatic islets. Globally, T1D accounts for a minority of cases (roughly 5–10%), while type 2 diabetes (T2D) accounts for over 90%. In most people, T1D follows autoimmune destruction of the insulin-producing beta cells and is therefore treated with exogenous insulin. T1D typically begins in childhood but can start at any age. T2D is driven largely by insulin resistance, in which tissues respond poorly to insulin. Unlike T1D, T2D is often treated with oral drugs, such as metformin, that improve insulin sensitivity (Magliano & Boyko, 2021).

Some children and adults with T1D develop insulin resistance, often first noticed as a rising insulin dose needed to keep glucose in range. However, current evidence does not support use of Metformin in T1D adolescents to improve HbA1c. Therefore, treatment of double diabetes in children remains an unmet clinical need (Figure 1). Measurement is the other problem. Though higher insulin requirement indicates insulin resistance, it is also influenced by diet, physical exercise, puberty, and other factors.

Clinicians look for signs such as acanthosis nigricans, a velvety darkening of the skin. The reference method is the hyperinsulinaemic-euglycaemic clamp (HEC). However, acanthosis nigricans is not specific, and HEC is too laborious for small clinics. As a result, alternative equations have been developed based on routinely measured clinical parameters. One such equation, the homeostasis model assessment of insulin resistance (HOMA-IR), is widely used in T2D. However, HOMA-IR relies on fasting insulin, which is typically raised in T2D but often very low or undetectable in T1D. It is therefore unsuitable for T1D.

In a systematic review of how insulin resistance and metabolic syndrome are assessed in T1D, we identified three equations (Khandagale et al., 2024). These combine waist circumference or waist-to-hip ratio, HbA1c, triglycerides or HDL-cholesterol, and blood pressure. However, few studies have tested whether they predict clinical outcomes. More importantly, the equations agree poorly with one another, so the choice of equation can change who is classified as insulin resistant.

As noted above, drugs used for insulin resistance in T2D have limited use in young people with T1D. This is the second unmet need. New treatments need a better understanding of the underlying biology. We recently examined blood-cell correlates of insulin sensitivity in 343 children and youth with T1D in western India. Insulin sensitivity was estimated using the equation from the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study (Duca et al., 2016). In our cohort, most participants had a normal-to-low BMI yet low estimated insulin sensitivity. Eosinophil counts were positively associated, and neutrophil, lymphocyte and platelet counts negatively associated, with insulin sensitivity. Most effects were modest, and they varied by age, sex and BMI (Figure 2). These associations differed from those reported in adults without T1D (Khandagale et al., 2026). These findings hint that double diabetes may differ biologically from insulin resistance in T2D. A single retrospective study cannot show this, so replication is essential.

Although T1D is a minority of diabetes, it affects children who will live with its consequences for decades, and it deserves dedicated attention. Inconsistent measurement methods and scarce data linking double diabetes to complications make interventions hard to design. Few biological studies also slow the search for new treatments, especially in children. In light of the above, three priorities can be set: (1) validating a T1D-specific insulin resistance index against the clamp in Indian youth; (2) multicentre paediatric T1D cohorts with standardised measurement and follow-up for complications; and (3) safety and efficacy trials of insulin sensitisers in younger children. We cannot treat what we cannot measure, and in young people with double diabetes we can do neither well yet.

References

Duca LM, Maahs DM, Schauer IE, Bergman BC, Nadeau KJ, Bjornstad P, Rewers M, Snell-Bergeon JK. Development and validation of a method to estimate insulin sensitivity in patients with and without type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2016 Feb 1;101(2):686-95.
Article DOI

Khandagale S, Bhor S, Oza C, Mondkar S, Kamble V, Agnihotri A, Singh A, Haque I, Pachpor T, Khadilkar A, Khare S. Peripheral blood cell counts as correlates of insulin sensitivity in children and youth with type 1 diabetes: A retrospective study from western India. Endocrine. 2026 Aug 10;91(1):269.
Article DOI

Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World journal of diabetes. 2010 May 15;1(2):36.
Article DOI

Magliano, D. J., & Boyko, E. J. (2021). IDF Diabetes Atlas (10th ed.). International Diabetes Federation.
Article DOI

Science Factors.

Evolution of proteins: a stride between stability and flexibility

Dr. N. Prakash Prabhu
0
The evolution of living forms from RNA molecules capable of performing functions and carrying information to more complex, refined systems is a journey of...

Teaching an Old Flavonoid New Tricks: What’s Next for Diabetic Wound Therapeutics

Dr. Suhani Sinha
0
India now has more than 77 million adults living with diabetes, and somewhere between 5% and 14% of these people will develop a foot...

Molecular Biomarkers and the Future of Bladder Cancer Assessment

Prof. Minakshi Vashist
0
Molecular Biomarkers and the Future of Bladder Cancer Assessment Bladder cancer does not behave in the same way in every patient. Even when clinical and...

Unlocking Natural Tick Resistance in Indigenous Cattle for Sustainable Livestock Farming

Dr. Jay Prakash Gupta
0
Ticks and tick-borne diseases are among the major challenges affecting milk production in India, causing considerable economic losses to dairy farmers. In addition to...

Predicting Molecular Excitations: New Tools for Future Light-Emitting Materials

Dr Manash Protim Borpuzari
0
An electron in a molecule absorbs energy and is excited to an electronically excited state; this is a simple molecular event that is the...

Can “Bioalchemistry” Transform Pharmaceutical Science Towards a Greener and Healthier Tomorrow?

Dr. Anil Kumar Kanuri
0
Pharmaceutical science has always been driven by one fundamental objective: improving human health. Yet, as the demand for medicines continues to increase, an important...

Climate, Catastrophes and the Growing Threat to Lung Health

Dr. Arundhati Garud
0
When a disaster strikes, people's immediate concerns revolve around survival, securing shelter, finding food, and ensuring the safety of their loved ones. However, even...

Five Colourful Crystals of One Molecular Pair: The Hidden Diversity of Pharmaceutical Co-crystals

Dr. Sonali Ghosh
0
At first glance, a crystal may seem like one of the simplest forms of matter. Molecules arrange themselves into an ordered structure, the crystal...